The new AI-powered platform could help scientists and health employees catch the next variant of Covid -9 before it spread, offering the world a crucial starting start in the fight against future pandemic.
Study: In Silico Genomic Monitoring with coverage provides and characterizes SARS-COV-2 variants. Credit Picture: Peterschreiber.media/shutterstock.com
Researchers at the Helmholtz Center on infection research and the German infection research center developed a web-based platform to identify and characterize the variations of serious acute respiratory syndrome (SARS-COV-2) early in development. The study is published in Nature communications.
Background
Sars-COV-2, the causal pathogen of the 2019 Crown Disease (COVID-19), is a one-sided RNA of positive logic with great ability to obtain mutations during its evolution. These mutations may potentially increase the ability to transmit, pathogenesis or immunological escape of the virus, leading to the appearance of more infectious or harmful variations, characterized as a variations of anxiety (VOC) or VOI variants (VOI) by the World Health Organization.
A high capacity of immunological escape allows Sars-COV-2 to avoid the anti-Immunization developed through previous infection or vaccination. This emphasizes the need to upgrade COVID-19 vaccines frequently to maintain their effectiveness against the variants in circulation.
Large-scale viral genomic surveillance programs have been implemented in several countries worldwide to constantly monitor the evolution and adaptation of SARS-COV-2 and the timely identification of new volatile organic compounds. This has led to the creation of a huge amount of viral genome sequence data in the Gisaid database. Although the Gisaid database has greatly helped researchers and public health officials to characterize the evolution of the virus, methods remain necessary to constantly interpret these sequences and immediately ensure the continuous effectiveness of vaccines.
In the current study, the researchers developed an online analysis method, the coverage system, for genomic monitoring of Sars-COV-2.
The coverage system
The coverage system analyzes the SARS-COV-2 genomic sequence data from the Gisaid database, which contains over 16.5 million sequences. The system constantly predicts and constantly characterizes the emerging dynamic VOIs by country of origin for the dynamics of executives and antigenic changes.
The system includes a series of statistics and bioinformatic methods, including the accurate test and correction of Fisher for multiple comparisons, comparing mutations that appear in the pins protein on the surface of different virals in a given month. Viral executives with significantly higher mutations than the average are projected to have a higher transmission or immune escape capacity. They then appear on the coverage platform in special graphics called “Heatmaps”, so that users can see when and where significant changes in the virus occur.
Validation of the system
The researchers looked at the credibility of the coverage system by analyzing the genome sequence data of the known volatile organic compounds, including SARS-COV-2’s OMICRON variant. They observed that the system can identify these sequences as VOCs on average 79 days before its name.
The system used a method that rates amino acid changes based on a viral immune escape capacity to detect SARS-COV-2 variants with antigenic lesions. These antigenic change ratings are calculated using a matrix that weighs mutations throughout the pins protein, not only in known antigenic positions. Compared to an indictment of experimental neutralization for validation.
At time heads, these antigenic ratings were increased in clear order, showing first variations that are only monitored, followed by Vois, and finally, more intensely, VOCs, which are considered particularly harmful.
Importance
The study describes the development and validation of a genomic surveillance platform, coverage, which is constantly monitoring the SARS-COV-2 genome sequence data to identify and characterize the possible VOI by circulating viral executives in time. It also proposes the degree of antigenic changes and alleles of the spike protein with specific amino acid changes that can offer a selective advantage.
The coverage system includes three new methods: one method detects possible VOI with a higher postdoctoral. A second method analyzes the dynamics of amino acid changes in all major surface proteins to identify those that can give a selective advantage. and a third method that grades the degree of antigenic lesions of each variant using a single -herself of immune escape.
The systematic evaluation of coverage shows that the system can determine 88% of VOIS and VOC defined by which, accurately 79% and withdrawal 72%, more than two months before their name. WTO were not missing and most of the lost generations were lower public health relevance (monitoring variants).
The forecasts made by coverage depends on the extent and quality of the ongoing viral genomic monitoring programs for individual countries. Analysis is done in a country and can also be affected by genetic effects of the population when the numbers of cases are low. Any reduction in genomic surveillance may thus affect its predictive ability.
Several other online platforms, including Nextstrain, Covariants, Covidcg, Evescape and Spikepro, monitor SARS-COV-2 variants and characterize their mutagenic frequencies. However, none of these platforms are constantly rating all traffic variations for a possible advantage and real -time antigenic change. They also do not provide a comparative evaluation against experimental antigenic data, as the coverage does.
In addition, the coverage system combines GISAID data with links with internet -based alternative resources. It offers open access details for additional information on selected variants, providing a comprehensive resource for viral genomic surveillance.
